Skip to main content

Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer.

Poel D, Buffart TE, Oosterling-Jansen J, Verheul HM, Voortman J

Publication: Exp Mol Med (2018) • Vol 50 • Page e454PMID: 29520111View on PubMed

Purpose

This paper investigated the effects of processing delay, addition of carrier RNA during extraction, and normalization method on the measurement of circulating microRNA (ci-miRNA) levels in plasma and serum specimens.

Conclusion

Circulating miRNA levels in serum and plasma increased with the addition of glycogen or MS2 alone and in combination but the effect was generally lowest when both carriers were used in combination. Normalization of circulating miRNA levels to spiked-in cel-miR-39-3p and endogenous miR-16-5p resulted in lower variability in CT than normalization to either alone in both plasma and serum.

Processing delays resulted in increased hemolytic index in serum and a more than 1.5-fold increase in the levels of miR-21-5p in two of the five serum specimens and a decrease in miR-142-3p in two different serum specimens.  In contrast, processing delay did not affect the hemolysis index of plasma specimens or levels of miR-21-5p and miR-92a-3p, but levels of miR-142-3p decreased by more than 1.5-fold in one of five specimens and increased more than 1.5-fold in three of five specimens, depending on time-point.

Intra-individual variability in ci-miRNA levels was small and limited to a few specimens.

Studies (3)

Purpose

The purpose of this study was to investigate the effects of adding glycogen or MS2 carrier RNA alone or in combination on the CT values for circulating miRNA in serum and plasma and to determine the best normalization strategy for ci-miRNA. Blood was collected from 10 head and neck squamous cell carcinoma (HNSCC) patients into plain BD Vacutainer tubes and BD Vacutainer EDTA tubes. Serum was obtained by centrifugation at 1500 x g for 10 min and plasma by centrifugation at 120 x g for 20 min followed by 360 x g for 20 min and 2700 x g for 10 min. Plasma and serum were pooled and stored at -80˚C. RNA was isolated in triplicate using the miRCURY RNA isolation kit with either no carrier, glycogen alone, MS2 alone, or a combination or glycogen and MS2. Cel-miR-39-3p was spiked-in during lysis. Extracted RNA was stored at -80˚C. Levels of miRNA were quantified by real-time PCR using the miRCURY LNA Universal RT microRNA kit. miRNA levels were normalized to cel-miR-39-3p or miR-16-5p alone or in combination.

Summary of Findings

The mean CT values for circulating miRNAs in serum decreased with the addition of glycogen (1.11±0.56), MS2 (2.36±0.34), and glycogen with MS2 (1.53± 0.63) but the magnitude of the decrease was miRNA-dependent. Similarly, the mean CT of circulating miRNAs in plasma decreased with the addition of glycogen (1.17±0.43), MS2 (0.83±0.14), and glycogen with MS2 (1.11± 0.15). As the addition of MS-2 also reduced the standard error of the mean (SEM) of the average CT values for all of the miRNAs tested in serum and two of five miRNAs in plasma, it was chosen for all other experiments.

Normalization of circulating miRNA levels to spiked-in cel-miR-39-3p and endogenous miR-16-5p resulted in lower variability in CT than normalization to either alone in both plasma and serum.

  • Biospecimens

    FluidBlood
    FluidPlasma
    FluidSerum
  • Preservation Types

    Frozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Serum
    Analyte Extraction and PurificationAnalyte isolation method
    Glycogen added
    MS2 added
    MS2 and Glycogen added
    Real-time qRT-PCR SpecificData handling
    Normalized to cel-miR-39-3p
    Normalized to cel-miR-39-3p and miR-16-5p
    Normalized to miR-16-5p